For the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure

5-day Doptelet® (avatrombopag) tablets

DOSING & SCHEDULING GUIDE

THINK WHAT YOU COULD DO WITH

MORE PLATELETS FOR PATIENTS UNDERGOING PROCEDURES

97% of patients taking DOPTELET increased platelets in time for their scheduled procedure*

*In pooled data from the ADAPT-1 and ADAPT-2 randomized, placebo-controlled studies (N=435). (Data on File)

INDICATION

DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

SELECTED IMPORTANT SAFETY INFORMATION

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Please see Important Safety Information on back page and accompanying Full Prescribing Information for DOPTELET (avatrombopag), also available at DOPTELET.com.

A Different Way To Increase Platelet Count

Once-daily oral dosing taken for 5 days.

PRESCRIBE

DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

START

DOPTELET is available in 2 tailored dosing options.

Based on the patient's baseline platelet count, instruct patients to take 40 mg (2 tablets) or 60 mg (3 tablets) of DOPTELET once daily with food for 5 consecutive days.

- In the case of a missed dose, patients should take the next dose of DOPTELET as soon as they remember
- Patients should not take 2 days of dosing at one time to make up for a missed dose and should take the next dose at the usual time the next day
- All 5 days of dosing should be completed

FOLLOW THE SCHEDULE

Start DOPTELET 10-13 days prior to a scheduled procedure

5 DAYS	1x DAILY WITH FOOD	TAKE DOPTELET ONCE DAILY FOR 5 DAYS WITH FOOD
4 DAYS	WAITING PERIOD	WAIT 4 DAYS FOR PLATELET COUNT TO RISE
4 DAYS	PROCEDURE WINDOW	4-DAY PROCEDURE WINDOW

Please see Important Safety Information on back page and accompanying Full Prescribing Information for DOPTELET (avatrombopag), also available at DOPTELET.com.

FOR HIGH BASELINE PLATELET COUNT 40 to <50 × 10^9/L: 40 mg (2 tablets)

- 1 carton of 10 tablets, 20 mg each
- Patients take 40 mg (2 tablets) once daily with food

FOR LOW BASELINE PLATELET COUNT <40 × 10^9/L: 60 mg (3 tablets)

- 1 carton of 15 tablets, 20 mg each
- Patients take 60 mg (3 tablets) once daily with food

Monitoring: Obtain a platelet count prior to administration of DOPTELET therapy and on the day of a procedure to ensure an adequate increase in platelet count.

Dova PHARMACEUTICALS 1SOURCE™

Get patients started on DOPTELET with support from Dova 1Source

Dova 1Source is the single point of contact providing patients with the resources they need, including a network of specialty pharmacies and financial support programs to access DOPTELET.

Learn more at Dova1Source.com

5-day Doptelet® (avatrombopag) tablets

5-day Doptelet® (avatrombopag) tablets

INDICATION
DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION FOR DOPTELET
Warnings and Precautions
DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Contraindications: None

Adverse Reactions
The most common adverse reactions (≥3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

To report suspected adverse reactions, contact Dova Pharmaceuticals at 1-844-506-DOVA (3682) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying Full Prescribing Information for DOPTELET (avatrombopag), also available at DOPTELET.com.

Dova™ PHARMACEUTICALS